MIDDLE EAST PHARMACEUTICAL INDUSTRIES COMPANY

Autres langues Middle East Pharmaceutical Industries Company

Actions

4016

SA160G51UO10

Produits pharmaceutiques

Marché Fermé - Saudi Arabian S.E. 14:20:00 26/08/2026			Varia. 5j.	Varia. 1 janv.
63,45 ^SAR	+2,17%		+7,00%	-0,15%

20/08	Avalon Pharma renouvelle une ligne de crédit de 50 millions de riyals saoudiens	MT
18/08	Bio-Thera Solutions et Avalon Pharma renforcent leur collaboration sur le BAT2406 (dupilumab) en Arabie saoudite et sur les marchés du Moyen-Orient et de l'Afrique du Nord	CI

Autres langues

20/08	Avalon Pharma Renews SAR50 Million Credit Facility
18/08	Bio-Thera Solutions and Avalon Pharma are deepening their collaboration on BAT2406 in Saudi Arabia and other Middle Eastern and North African markets
18/08	Avalon Pharma Wins 15-year Exclusive Biosimilar License Deal in Saudi Arabia
10/08	Avalon Pharma Declares H1 Dividend
10/08	Middle East Pharmaceutical Industries Company Announces Cash Dividends for the First Half of 2026, Payable on September 15, 2026
09/08	Middle East Pharmaceutical Industries Company Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Avalon Pharma Posts Growth in H1 Net Profit, Revenue
14/05	Saudi Arabia's Edaa Executes Securities Quantity Increase for Avalon Pharma
12/05	Middle East Pharmaceutical Industries Company Reports Earnings Results for the First Quarter Ended March 31, 2026
12/05	Saudi Exchange Sets Fluctuation Limits for Avalon Pharma's Capital Increase
06/05	Avalon Pharma Q1 profit SAR 26.9 million
06/05	Avalon Pharma Logs Higher Q1 Profit, Revenue
16/04	Avalon Pharma appoints Ahmad Shaher Al Tabbaa as chairman
06/04	Saudi Regulator OKs Avalon Pharma's Capital Hike Request
09/03	Avalon Pharma Raises Dividend for H2 2025
08/03	Avalon Pharma H2 dividend per share SAR 1.32
08/03	Middle East Pharmaceutical Industries Company Announces Interim Cash Dividends for the Second Half of 2025, payable on 07 April 2026
08/03	Middle East Pharmaceutical Industries Company Reports Earnings Results for the Full Year Ended December 31, 2025
04/03	Tadawul Shares Surge With Oil Prices Amid Corporate Earnings Buzz
04/03	Avalon Pharma Posts Higher FY25 Profit, Revenue
04/03	Avalon Pharma FY profit 97.01 mln riyals
04/02	Tadawul Shares Close Higher; Saudi Arabia Earmarks $2 Billion for Turkish Renewable Projects
04/02	Avalon Pharma Lands Exclusive Marketing Rights for Keytruda Biosimilar in Saudi Arabia, MENA
04/02	Avalon Pharma contract sign off with Bio-Thera Solutions
04/02	Middle East Pharmaceutical Industries Co. Announces Contract Sign Off with Bio-Thera Solutions Inc